Clinical trial Recruiting at 4 sites Observational Ages 70 to 120

Evaluating statin treatment in frail older patients after stroke or TIA

Official title: StAtins in Frail OldEr Patients with Ischemic Stroke or Transient Ischemic Attack - the Prospective Cohort Study

Run by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · NCT06785740 · Data updated 2026-11-12

This study is testing whether keeping older, frail patients on statins after a stroke or TIA helps them feel better and avoid serious heart problems compared to stopping the medication.

More Ischemic Stroke trials

Quick facts

Study typeObservational
Ages70 Years to 120 Years
SexAll
Enrollment300 (estimated)
SponsorAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Academic / other
Locations4 sites (Almere Stad and 3 other locations)
StatusRecruiting
StartedNovember 1, 2024
Main results expectedSeptember 2029
Study endsSeptember 2029
Registry record updatedJanuary 21, 2025
Trial IDNCT06785740 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are frail individuals aged 70 and older who have recently suffered an ischemic stroke or TIA and are currently on statin therapy.

Probably not a fit

Patients who are very frail with a life expectancy of less than six months or those with serious adverse reactions to statins will not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to assess the impact of continuing versus discontinuing statin therapy in frail individuals aged 70 and above who have recently experienced an ischemic stroke or transient ischemic attack (TIA). The study will follow participants for two years to evaluate their health-related quality of life and the incidence of major adverse cardiovascular events (MACE). Given the conflicting guidelines on statin use in older patients, this research seeks to fill the gap in evidence regarding the efficacy of statins in frail older adults. Participants will be assessed based on their frailty status using a validated scale.

Why it matters

Potential benefit: If successful, this study could provide critical insights into the optimal management of statin therapy in frail older patients, potentially improving their quality of life and reducing adverse cardiovascular events.

How similar studies have gone: While there is limited evidence specifically addressing frail older adults, previous studies have shown that statins can reduce major vascular events in older populations, indicating potential for success in this cohort.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* age = 70 years or older at the time of ischemic stroke or TIA;
* inclusion within 6 weeks after diagnosis of ischemic stroke or TIA;
* already using statin therapy at the time of the index event;
* frailty as defined by a pre-event score of 4-7 and/or post-event score of 6-7 on the validated Clinical Frailty Scale.

Exclusion Criteria:

* Previous serious adverse drug reactions (defined as an adverse reaction that results in death, is life-threatening, requires hospitalisation or prolongation of existing hospitalisa-tion, results in persistent or significant disability or incapacity, or is a birth defect32) to statins or other contraindications to statin use.
* Very severe frailty or very limited life expectancy (\< 6 months) as defined by a score \>= 8 points on the validated Clinical Frailty Scale.
* Inability to communicate in Dutch.
* Inability to respond to questions, either independently or with the assistance of a proxy.
* Inability or unwillingness to provide written informed consent, either independently or with the assistance of a proxy.

Where it's running

  • Flevoziekenhuis
    Almere Stad, Netherlands
    Recruiting
  • Amsterdam UMC, location AMC
    Amsterdam, Netherlands
    Recruiting
  • Catharina Ziekenhuis
    Eindhoven, Netherlands
    Recruiting
  • Isala Klinieken
    Zwolle, Netherlands
    Recruiting

Study contacts

  • Principal investigator: Renske van den Berg-Vos, Prof. dr. — Amsterdam UMC, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
  • Study coordinator: Susanna R Prins, MSc
  • Email: s.r.prins@amsterdamumc.nl
  • Phone: 0031 20 566 9111

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.